NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress

Earlier in January 2026, Viking Therapeutics reported peer-reviewed Phase 2 VENTURE trial results for its dual GLP‑1/GIP agonist VK2735, showing statistically significant weight loss of up to 14.7% over 13 weeks with generally mild to moderate side effects. With Phase 3 VANQUISH-1 and VANQUISH-2 trials now underway and enrollment largely completed, Viking is moving VK2735 toward longer-term efficacy and safety evaluation in both obesity and type 2 diabetes populations. We’ll now examine how...
NasdaqGM:WLDN
NasdaqGM:WLDNProfessional Services

Can Rising Data Center Energy Demands Turn Willdan Group’s Commercial Business Into a Core Profit Driver (WLDN)?

Recent commentary highlighted that Willdan Group is seeing increased demand from state and local governments, utilities, and commercial customers for energy optimization and infrastructure efficiency services, including projects linked to data center energy use. An important angle is that Willdan’s commercial segment, currently a smaller share of revenue, is being highlighted as a potential growth engine as more companies seek to curb rising energy costs. We’ll now examine how this increased...
NasdaqGS:CALM
NasdaqGS:CALMFood

Why Cal-Maine Foods (CALM) Is Down 5.3% After Q2 Miss and Buyback Completion - And What's Next

Cal-Maine Foods reported past second-quarter 2025 results showing sales of US$769.5 million and net income of US$102.76 million, alongside a US$0.72 per-share cash dividend under its variable policy and completion of a US$124.84 million share repurchase program covering 2.87% of shares. The company pointed to the normalization of egg prices after last year’s supply shock while leaning more on specialty eggs and prepared foods to support earnings resilience. We’ll now examine how the earnings...
NYSE:USPH
NYSE:USPHHealthcare

U.S. Physical Therapy (USPH) Is Up 8.1% After 17.3% Revenue Gain And Upbeat Analyst Sentiment

In recent days, U.S. Physical Therapy, Inc. has drawn heightened investor attention as revenue rose 17.30%, supported by what analysts describe as compelling growth prospects and a robust operating model. What stands out is the combination of this strong revenue performance with largely positive analyst sentiment, which together underpin a reinforced confidence in the company’s long-term business trajectory. With strong analyst enthusiasm around its growth prospects now in focus, we’ll...
NasdaqGS:ALGM
NasdaqGS:ALGMSemiconductor

Allegro MicroSystems (ALGM) Valuation Check After New Power And Sensor Product Launches

Allegro MicroSystems (ALGM) has drawn fresh attention after launching new Power Thru isolated gate drivers and the ACS37200 current sensor, targeting efficiency and power density needs in EVs, AI data centers, industrial automation, and clean energy. See our latest analysis for Allegro MicroSystems. The recent product launches and the upcoming February Analyst Day have arrived during a strong run, with a 1 month share price return of 20.7% and a 1 year total shareholder return of 37.82%...
NYSE:LRN
NYSE:LRNConsumer Services

Is Stride (LRN) Pricing Reflect Its DCF Value After Recent Share Price Volatility

If you are wondering whether Stride's current share price lines up with its underlying value, you are not alone. This article is built to help you assess that clearly. Stride shares last closed at US$70.38, with returns of 3.8% over the past week, 10.1% over the past month, 8.9% year to date and a 36.8% decline over the past year, alongside gains of 121.5% over three years and 188.3% over five years. Recent coverage has focused on Stride's position in online education and changing demand for...
NYSE:GME
NYSE:GMESpecialty Retail

Is It Time To Reassess GameStop (GME) After Its Recent Share Price Swings

If you are wondering whether GameStop at around US$21.02 reflects its true worth, you are not alone. This article focuses squarely on what that price might represent for you as a shareholder or potential investor. The stock has been choppy, with a 1% decline over the last 7 days, a 5% decline over 30 days, a 2% gain year to date, a 24% decline over 1 year, and a 118% gain over 5 years. This pattern hints at changing views on both risk and long term potential. Recent attention around GameStop...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Assessing Liquidia (LQDA) Valuation After Analyst Upgrades And Strong Yutrepia Revenue Update

Liquidia (LQDA) is back in focus after analysts cited stronger than expected preliminary fourth quarter 2025 revenue of about US$90.1 million from Yutrepia inhalation powder and higher patient uptake as key drivers of sentiment. See our latest analysis for Liquidia. The upbeat Yutrepia update and recent conference appearance at the J.P. Morgan Healthcare Conference have arrived alongside strong momentum, with a 90 day share price return of 77.89% and a very large 5 year total shareholder...
NYSE:AWI
NYSE:AWIBuilding

Is Armstrong World Industries (AWI) Fairly Priced After Strong Multi‑Year Share Price Gains

If you are wondering whether Armstrong World Industries is priced attractively right now, it helps to step back and look at how its market value lines up with the underlying business. The share price closed at US$195.76, with returns of 3.4% over the last 7 days, 5.9% over the last 30 days, a small year to date decline of 0.6%, and gains of 33.3% over 1 year, 172.6% over 3 years and 153.0% over 5 years. Recent news coverage has focused on Armstrong World Industries as investors reassess...